Serum HER2 extracellular domain as a predictive biomarker for trastuzumab deruxtecan treatment response in HER2-positive gastric cancer: a real-world study
Baseline serum HER2 ECD may be a potential non-invasive predictor of T-DXd response in HER2-positive AGC, particularly in IHC 2+/ISH+ cases. Dynamic HER2 ECD level changes during therapy may also reflect treatment response.
Authors
- H. Taniguchi
- Y. Narita
- Kazunori Honda (ORCID: https://orcid.org/0000-0001-5090-9771)
- Koshi Takahashi (ORCID: https://orcid.org/0000-0003-0087-7905)
- Ryosuke Kumanishi
- M. Ando
- Masahiro Tajika
- Tadahisa Fukui
- Shigenori Kadowaki
- Kei Muro
- Toshiki Masuishi
Institutions
- Aichi Cancer Center (JP)
- Yamagata University Hospital (JP)
Publication Details
- Journal
- Therapeutic Advances in Gastroenterology
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1177/17562848251410771
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00